Introduction
Obstructive sleep apnoea (OSA) is very common in patients with Type 2 diabetes and is characterized by recurrent episodes of upper airway obstruction associated with recurrent oxygen desaturations, cyclical changes in blood pressure (BP), heart rate and intrathoracic pressure, as well as recurrent arousals from sleep and changes in sleep architecture (Tahrani et al., 2013b) .
We have previously shown that OSA was associated with foot insensitivity (based on 10g monofilament test) and diabetic peripheral neuropathy (DPN)(based on the Michigan Neuropathy Screening Instrument MNSI) (Tahrani et al., 2012a) . These assessments are largely based on large fiber neuropathy; while the relationship between OSA and small fiber neuropathy is unknown. Intra epidermal nerve fiber density (IENFD) is considered an accurate and reproducible measure of early diabetic neuropathy and the "gold standard" for small fiber neuropathy (England et We have also shown previously that OSA was associated with impaired cutaneous microvascular function (assessed by Laser Speckle Contrast Imaging technique) and impaired responses to nitric oxide (Tahrani et al., 2012a) . OSA was associated with increased nitrosative stress and oxidative stress in patients with Type 2 diabetes which might have contributed to the associations between OSA and impaired microvascular function and DPN (Tahrani et al., 2012a) . Hyperglycemia-induced nitrosative and oxidative stress play an important role in the development of vascular disease in patients with diabetes, via the activation of Poly ADP ribose polymerase (PARP), the inhibition of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and the activation of several pathways (such as the polyol pathway and advanced-glycation end product (AGE)) resulting in inflammation, endothelial dysfunction and microvascular disease (Brownlee, 2005; Tahrani et al., 2010) . Hence, we hypothesized that OSA is associated with PARP activation in patients with Type 2 diabetes which can mediate the relationship between OSA and nitrosative stress and endothelial dysfunction, which we described previously (Tahrani et al., 2012a) .
PARP activation and oxidative stress have also been shown to play an important role in the pathogenesis of diabetic foot ulceration (DFU) (Tahrani et al., 2012b) . Based on the association between OSA and DPN, abnormal 10g monofilament, oxidative and nitrosative stress and possibly PARP activation, we hypothesized that OSA is associated with DFU in patients with Type 2 diabetes.
Hence the primary aim of this study is to examine the relationship between OSA and IENFD and PARP activation in the skin of patients with Type 2 diabetes. A secondary aim is to explore whether there is a link between OSA and DFU in this study population.
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Methods:
We conducted an observational cross-sectional study in adults with Type 2 diabetes, the results of which have been published previously (Tahrani et al., 2012a Pambianco et al., 2011) . Foot insensitivity to a 10-g monofilament (applied to 10 foot locations) was defined as < eight correct responses (Pambianco et al., 2011) .
OSA was assessed by a single overnight home-based cardio-respiratory sleep study using a portable hours of adequate recordings were repeated and excluded if the quality remained poor. All sleep studies were scored independently by two researchers.
All patients of the original study were approached to provide skin samples to assess IENFD and %PAR stained nuclei, and skin biopsies were performed on patients who consented. Skin biopsies were obtained from the mid-thigh level under local anesthetic and using aseptic techniques.
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IENFD was assessed as we described previously (Tahrani et al., 2012b) and recommended by others (Lauria et al., 2010) . Four randomly selected 50 µm sections were immunohistochemically stained using a free floating protocol with rabbit anti-human polyclonal PGP9.5 antibody (Biogenesis 1:1200). Individual ENFs were counted as they passed through the basement membrane. Negative controls comprised replacing the PG 9.5 antibody with rabbit immunoglobulin. Epidermal nerve counts were expressed as the number of fibers per millimeter of epidermis.
PARP activity was measured using immunohistochemical method that quantifies the accumulation of PAR, the product of the PARP activation (Obrosova et al., 2004; Szabó et al., 2002) . PAR was assessed as we described previously (Tahrani et al., 2012b) . Paraffin sections (4µm) were dewaxed and endogenous peroxidases removed and blocked. After antigen retrieval, mouse monoclonal anti PAR antibody (1:400) (Enzo Life Sciences, Exeter, UK) was applied and then washed. Sections were incubated with ImPRESS universal reagent (Vector Laboratories). Immunoreactivity was revealed using diaminobenzidine (Vector Laboratories) and sections counterstained with haematoxylin. The number of stained and unstained endothelial nuclei were counted in ten fields from each section, using 400X magnification resulting in 300-400 nuclei being assessed. The results are expressed as % PAR stained nuclei (Szabó et al., 2002) .
Foot ulceration was assessed in the whole of the original study population (i.e. not only those who consented for skin biopsies) during foot exam, and based on question 8 of the MNSIq "Have you
ever had an open sore on your foot?"
All Laboratory, sleep and clinical assessments were blinded.
Data analysis was performed using SPSS 22.0 software (SPSS Inc, Chicago, USA). Data are presented as mean (SD). Differences between independent groups were assessed by analysis of variance (ANOVA). Categorical variables were compared using the Chi-squared test or Fisher's exact test.
Correlations between continuous variables were performed using the Pearson or Spearman tests.
Multiple linear regression (forced entry method) was used to assess independent associations of continuous outcomes and independent variables (for example the relationship between IENFD and OSA and AHI). Non-normally distributed variables were log transformed when used in the linear regression models (AHI was transformed to log (AHI+1), 1 was added as some AHI values were 0).
Dummy variables were used in linear regression models if the independent variable was categorical with more than 2 categories (such as OSA status: no OSA, mild OSA and moderate to severe OSA). In multiple linear regression, residual distribution was examined and multicollinearity was assessed using correlations, the tolerance, variance inflation factor (VIF) and condition index. To assess
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whether OSA status or OSA severity are associated with DFU, multiple logistic regression (forced entry method) was used where DFU was the dependent variable and OSA and other variables were the independent variables. Variables included in the regression models were based on known outcome-related risk factors. A p value < 0.05 was considered significant.
Results
Data regarding DFU was available in the whole population of the original study (n=234), of which 52 patients agreed to have skin biopsies (Figure 1 ). PAR staining was available for all 52 patients while IENFD results were available for 48 patients. Of the 52 patients who had skin biopsies, the prevalence of OSA was 83% (43/52), with 24 (46%) mild OSA and 19 (37% ) moderate to severe OSA.
Of the original study population the prevalence of no OSA, mild OSA and moderate-severe OSA was 36% (83/234), 39% (90/234) and 26% (61/234).
The skin biopsy study population characteristics in accordance with OSA severity are summarized in Table 1 . There were no statistically significant difference between patients with and without OSA with regards to important characteristics including age, diabetes duration, lipids profile, HbA1c, blood pressure (BP) and body mass index (BMI). There was a non-significant stepwise reduction in ). There were more men and more White Europeans in patients with OSA, but these differences were not statistically significant. There were no differences in alcohol intake or smoking between groups. Insulin prescription was similar across groups and a high proportion of all groups were prescribed BP lowering and lipid lowering treatments.
OSA and IENFD
Results of IENFD were available in 48 patients (4 patients did not have enough tissue left to perform PAR immunostaining but not IENFD) , 9 patients with no OSA, 22 with mild OSA and 17 with moderate to severe OSA.
In ANOVA, there was a significant reduction in IENFD across groups (12.75±1.93 vs. 10.55±1.62 vs.
9.42±1.16 fibers/mm of epidermis for no OSA, mild OSA and moderate to severe OSA respectively, p<0.001) (Figure 2 ). IENFD correlated negatively with the AHI (r=-0.51, p<0.001) and ODI (r=-0.33, p=0.02). There were no associations between IENFD and time spent with oxygen saturation < 90% (r=0.08, p=0.57) or nadir nocturnal oxygen saturation (r=0.02, p=0.9). was an association between log (AHI+1) and %PAR stained nuclei when log (AHI+1) was used in the model instead of OSA (B=13.67, p=0.025). The regression coefficient suggests that higher AHI was associated with higher %PAR stained nuclei.
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OSA and DFU
The baseline characteristics of the original study (n=234) in relation to OSA status are summarized in Table 2 and were published previously (Tahrani et al., 2012a) . Patients with OSA were older, heavier and had longer diabetes duration and higher prevalence of peripheral vascular disease (PVD, based on the patients electronic records). OSA was also more common in men and in White Europeans.
OSA patients were prescribed more insulin and anti-hypertensive medication compared to those without OSA.
The prevalence of DFU on clinical examination was 3.4% (n=8). There was a stepwise increase in the prevalence of DFU in patients with no OSA vs. mild OSA vs. moderate to severe OSA (0% (0) vs. 2.2%
(2) vs. 10% (6), p=0.004).Due to the small number of patients with DFU on clinical examination, we could not perform logistic regression to assess independent associations.
Based on question 8 of the MNSIq, 47/234 (20.1%) patients had past history of DFU. The prevalence of a past history of DFU was significantly greater in patients with OSA (7.1% (6/84) vs. 28.1% (25/89) 
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Conclusions
We have shown that OSA and AHI are associated with lower IENFD, AHI is associated with PARP activation and OSA is associated with DFU in patients with Type 2 diabetes. To the best of our knowledge, this is the first report to describe the relationships between OSA and IENFD, PARP activation and DFU in patients with Type 2 diabetes.
IENFD has been shown to have high sensitivity and specificity to diagnose DPN, particularly small IENFD was found to correlate inversely with thermal thresholds and pain severity (Malik et al., 2011 ).
The lower IENFD in patients with OSA and Type 2 diabetes vs. patients with Type 2 diabetes only suggest that OSA is associated with small fiber neuropathy in patients with Type 2 diabetes which complements our previous finding that OSA was associated with clinically evident DPN and foot insensitivity suggesting that OSA in patients with Type 2 diabetes is associated with both small and large fibers neuropathy. Even mild OSA was independently associated with lower IENFD, which might reflect the relatively long diabetes duration in these patients that could amplify the impact of mild OSA in vulnerable tissues. Thus, assessing patients with shorter diabetes duration might yield different results. This finding was also similar to our previous study showing that mild OSA was independently associated with clinically evident DPN (Tahrani et al., 2012a) . Obesity also is an established risk factor for DPN and SDB (Tahrani et al., 2013b; Tesfaye et al., 2005) ; in addition IENFD has been shown to correlate negatively with BMI (Smith and Singleton, 2013) . However, in this study there were no significant differences in BMI between groups and the associations between IENFD and SDB remained significant despite adjustment for BMI in the multivariable analysis.
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PARP activation, secondary to oxidative stress-induced DNA damage, has been shown to play an important role in the pathogenesis of DPN and endothelial dysfunction in patients with diabetes (Obrosova et al., 2004; Szabó et al., 2002) . In our study, PARP activation was independently associated with higher AHI; this is likely to be due to DNA damage secondary to oxidative stress in patients with OSA and type 2 diabetes. We have shown previously that OSA in patients with type 2 diabetes was associated with increased oxidative and nitrosative stress (Tahrani et al., 2012a) . We also found that OSA is independently associated with DFU in patients with Type 2 diabetes. This association was independent of important risk factors such as PVD, BMI, age, diabetes duration and This study has several limitations, most importantly its cross-sectional design where causality cannot be proven. Although several reasons might explain how OSA might result in lower IENFD, PARP activation and DFU, it is plausible for neuropathy to result or worsen OSA by its impact on upper airway function and the ventilatory drive. Hence, it is possible that the relationship could be bidirectional. The rather small sample size is another limiting factor but not many patients were willing to have skin biopsy which is a mini-invasive procedure, but 52 patients is comparable (and even more) than many other studies of skin biopsies in patients with Type 2 diabetes.
Our study also has strengths. The population of the study were well characterized and this is the first report to examine the relationship between OSA and IENFD, PARP and DFU in patients with type 2
diabetes. This is also the first report to show a relationship between OSA and IENFD and PARP activation in humans.
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